Page last updated: 2024-12-06

penicillin v benzathine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID64725
CHEMBL ID1396177
SCHEMBL ID418029
MeSH IDM0065190

Synonyms (29)

Synonym
cas-5928-84-7
NCGC00017051-01
D02405
penicillin v benzathine (usp)
penicillin v benzathine [usan]
v-pen ped forte
penicillin v benzathine
biphecillin
(2s,5r,6r)-3,3-dimethyl-7-oxo-6-(2-phenoxyacetamido)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid compound with n,n'-dibenzylethylenediamine (2:1)
bicillin-5
bicillin v
benzathine penicillin v
benzathine phenoxymethylpenicillin
einecs 227-667-2
n,n'-dibenzylethylenediammonium (2s-(2alpha,5alpha,6beta))-bis(3,3-dimethyl-7-oxo-6-((phenoxyacetyl)amino)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate)
unii-3t4emh59zu
penicillin v benzathine [usan:usp]
3t4emh59zu ,
SCHEMBL418029
phenoxymethylpenicillin benzathine [who-dd]
penicillin v compd with dibenzylethylenediamine
penicillin v benzathine [usp impurity]
benzathine phenoxymethylpenicillin [mart.]
penicillin v compd with dibenzylethylenediamine [mi]
benzathine phenoxymethyl penicillin
penicillin benzathine phenoxymethyl
CHEMBL1396177
DTXSID80207999
Q4890751

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"Comparative randomized opened pharmacokinetic evaluation of benzathine benzylpenicillin in three dosage forms was performed."( [A comparative evaluation of the pharmacokinetics of different forms of benzathine benzylpenicillin].
Belov, BS; Cherniak, AV; Makarova, RA; Sidorenko, SV, 2000
)
0.31

Bioavailability

ExcerptReferenceRelevance
"The absorption rate and serum level curves of two commercial phenoxymethylpenicillin mixture preparations were compared in adult volunteers."( Absorption of penicillin V from mixture formulations. Comparison of potassium and benzathine salts.
Heikinheimo, M; Hovi, T, 1981
)
0.26

Dosage Studied

ExcerptRelevanceReference
"In a randomized, prospective, multicenter study the clinical and bacteriological efficacies of three dosage schedules with two different salts of oral penicillin V suspensions (regimen 1: potassium salt of penicillin V, 50,000 U/kg of body weight per day in three divided doses; regimen 2: benzathine salt of penicillin V, 50,000 U/kg of body weight per day in two divided doses; and regimen 3: benzathine salt of penicillin V, 100,000 U/kg of body weight in two divided doses) for the treatment of streptococcal pharyngitis were evaluated."( Randomized evaluation of benzathine penicillin V twice daily versus potassium penicillin V three times daily in the treatment of group A streptococcal pharyngitis. Pharyngitis Study Group.
Kaufhold, A, 1995
)
0.29
"Comparative randomized opened pharmacokinetic evaluation of benzathine benzylpenicillin in three dosage forms was performed."( [A comparative evaluation of the pharmacokinetics of different forms of benzathine benzylpenicillin].
Belov, BS; Cherniak, AV; Makarova, RA; Sidorenko, SV, 2000
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzathine(2+) salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency17.78280.011212.4002100.0000AID1030
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency3.98110.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency0.00630.00255.840031.6228AID899
lamin isoform A-delta10Homo sapiens (human)Potency0.00400.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (63.64)18.7374
1990's2 (9.09)18.2507
2000's1 (4.55)29.6817
2010's3 (13.64)24.3611
2020's2 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.23 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index4.15 (4.65)
Search Engine Demand Index59.80 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (42.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (13.64%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (4.55%)4.05%
Observational0 (0.00%)0.25%
Other18 (81.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]